The discovery of the role of anti-CTLA-4 therapy on anti-tumor immunity ultimately led to the first and only FDA approval of anti-CTLA-4 immunotherapy to date, ipilimumab, in 2011. This evidence concerns the gene CTLA4 and neoplasm.